Osaka, Japan, April 5, 2024 - Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino) announced that it has decided changes of the Board of Directors, Audit & Supervisory Board Members and Corporate Officers at the meeting of the Board of Directors held today.
　The appointments for candidates of the Board of Directors and Audit & Supervisory Board Members will be resolved at the 76th Annual Shareholders Meeting scheduled for June 2024. The changes and appointments of the Board of Directors and Corporate Officers will be officially decided at the meeting of the Board of Directors to be held on the same day after the Annual Shareholders Meeting.

1. Changes of the position of the Board of Directors (scheduled for June 2024):
   Except for the following Board of Director, incumbent of the Board of Directors will be re-appointed.
   - Resigning Board of Director:

   Kiyoaki Idemitsu

   Executive Officer / Chief Officer, Clinical Development

2. Changes of Audit & Supervisory Board Members (scheduled for June 2024):
   Except for the following candidates of Audit & Supervisory Board Members, the incumbent Members will be in term.
   - New candidate of Audit & Supervisory Board Member

   Kiyoaki Idemitsu

   - Resigning Audit & Supervisory Board Member

   Katsuyoshi Nishimura *: After resigning, he will be appointed as a part-time adviser.

   Yasuo Hishiyama(outside) will be re-appointed.

3. Changes of Corporate Officers (scheduled for June 2024):
   Except for the following candidates of Corporate Officers, incumbent Corporate Officers will be re-appointed.
   - New candidate of Corporate Officers

   Hirokazu Kitada	Senior Director, Osaka Branch Sales Division
   Yasushi Hirota	Executive Director, Corporate Regulatory Compliance, Safety and Quality Assurance
   Seishi Katsumata	Executive Director, Discovery & Research, Research Project Management Division
   Kunihiko Ito	President, Ono Pharma USA，Inc.

＜ Reference ＞
The followings are the appointments of the Board of Directors, Audit & Supervisory Board Members as well as Corporate Officers (scheduled for June 2024).
*: Candidates of the Board of Directors, and Audit & Supervisory Board Members for subject to approval at the 76th Annual Shareholders Meeting

The Board of Directors:

- Gyo Sagara*	Representative Director, Chairman of the Board and Chief Executive Officer
- Toichi Takino*	Representative Director, President and Chief Operating Officer
- Toshihiro Tsujinaka*	Representative Director, Executive Vice President / Executive Director, Corporate Strategy & Planning, Business Design, Sustainability Promotion
- Masao Nomura*	Outside Director
- Akiko Okuno*	Outside Director
- Shusaku Nagae*	Outside Director

Audit & Supervisory Board Members:

- Hironobu Tanisaka	Audit & Supervisory Board Member (full-time)
- Kiyoaki Idemitsu*	Audit & Supervisory Board Member (full-time)
- Yasuo Hishiyama*	Outside Audit & Supervisory Board Member
- Akiko Tanabe	Outside Audit & Supervisory Board Member

Corporate Officers:

- Akira Takada	Corporate Executive Officer / Executive Director, CMC & Production
- Satoshi Takahagi	Corporate Executive Officer / Executive Director, Sales and Marketing, Primary Care Business Division
- Hiromu Habashita	Corporate Officer / Deputy Executive Director, Discovery & Research
- Shinji Takai	Corporate Officer / Head of Medical Affairs
- Masaki Ito	Corporate Officer / Division Director, Corporate Strategy & Planning, Business Management Division, Business Management Department, Finance & Accounting / President, Ono Digital health Investment, GK.
- Tatsuya Okamaoto	Corporate Officer / Executive Director, Clinical Development, Oncology Clinical Development Division, Global Project Management
- Masayuki Tanigawa	Corporate Officer, Executive Director, Corporate Development & Strategy
- Takehiro Yamada	Corporate Officer / Senior Director, Risk & Compliance Management Department
- Hirokazu Kitada	Corporate Officer / Senior Director, Osaka Branch Sales Division
- Yasushi Hirota	Corporate Officer / Executive Director, Corporate Regulatory Compliance, Safety and Quality Assurance
- Seishi Katsumata	Corporate Officer / Executive Director, Discovery & Research, Research Project Management Division
- Kunihiko Ito	Corporate Officer / President, Ono Pharma USA, Inc.